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Editor’s key points
† Preoperative anaemia is a
serious but treatable
condition.
† Preoperative
haemoglobin
measurement (28 days)
should allow time for
treatment.
† Abnormalities should be
investigated and treated
before operation.
† An algorithm to guide
management is
proposed.
Summary. Previously undiagnosed anaemia is common in elective orthopaedic surgical
patients and is associated with increased likelihood of blood transfusion and increased
perioperative morbidity and mortality. A standardized approach for the detection,
evaluation, and management of anaemia in this setting has been identified as an unmet
medical need. A multidisciplinary panel of physicians was convened by the Network for
Advancement of Transfusion Alternatives (NATA) with the aim of developing practice
guidelines for the detection, evaluation, and management of preoperative anaemia in
elective orthopaedic surgery. A systematic literature review and critical evaluation of the
evidence was performed, and recommendations were formulated according to the
method proposed by the Grades of Recommendation Assessment, Development and
Evaluation (GRADE) Working Group. We recommend that elective orthopaedic surgical
patients have a haemoglobin (Hb) level determination 28 days before the scheduled
surgical procedure if possible (Grade 1C). We suggest that the patient’s target Hb before
elective surgery be within the normal range, according to the World Health Organization
criteria (Grade 2C). We recommend further laboratory testing to evaluate anaemia for
nutritional deficiencies, chronic renal insufficiency, and/or chronic inflammatory disease
(Grade 1C). We recommend that nutritional deficiencies be treated (Grade 1C). We
suggest that erythropoiesis-stimulating agents be used for anaemic patients in whom
nutritional deficiencies have been ruled out, corrected, or both (Grade 2A). Anaemia
should be viewed as a serious and treatable medical condition, rather than simply an
abnormal laboratory value. Implementation of anaemia management in the elective
orthopaedic surgery setting will improve patient outcomes.
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The overall prevalence of anaemia in the general population
increases with age, so that in the elderly (.65 yr old), the
prevalence of anaemia as defined by the World Health
Organization (WHO)1 is 11% and 10.2% for men and
women, respectively.2 Previously undiagnosed anaemia is
therefore common in elective surgical patients;3 the preva-
lence depending on age and associated co-morbidities
such as diabetes, congestive heart failure, and other inflam-
matory conditions. In a US national audit of patients under-
going elective orthopaedic surgery,4 35% of the patients
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were found to have haemoglobin (Hb) levels ,13 g dl21 at
preadmission testing. Many of these patients are women
and approximately one-third of these are the result of iron
deficiency.2 5 6 Similarly, in a large single-institution study
in Spain, preoperative Hb was ,13 g dl21 in 19.4% of the
patients, and the prevalence of haematinic deficiencies was
33% for iron, 12.3% for vitamin B12, and 3% for folate.
7
These results were also corroborated by a large series from
Egypt and Scotland.8 The remaining anaemias are attributed
to chronic inflammatory disease, chronic renal disease (CKD),
or unknown causes.2 9
Preoperative anaemia is associated with increased mor-
bidity10 11 and mortality10 12 13 after orthopaedic surgery,
and exposure to allogeneic blood transfusions.14 – 16 Admis-
sion Hb levels have also been shown to have an impact on
postoperative functional recovery in an elderly population
with hip fractures11 17 18 and on the quality of life after
total hip arthroplasty.19
Background
Impact of preoperative anaemia on clinical outcomes
The impact of preoperative anaemia on perioperative mor-
tality can be illustrated in Jehovah’s Witness patients (who
refuse allogeneic transfusion for religious reasons) under-
going surgery. In a retrospective study of 1958 Jehovah’s
Witness patients undergoing non-cardiac surgery, a pre-
operative Hb concentration of ≤10 g dl21 was associated
with a significant increase in perioperative mortality.10
This increase was significantly more pronounced in
patients with cardiovascular disease (CVD) than in patients
without known CVD. A decrease in Hb of ≤2 g dl21 in the
absence of CVD was not associated with an increased risk
of postoperative death. The risk of death was highest in
patients with CVD along with a ≥4 g dl21 or greater
decline in Hb. In a subsequent analysis, for all patients,
postoperative Hb levels ≥7 g dl21 were associated with
some morbidity but no mortality; but for every 1 g dl21
decrement below 7 g dl21, mortality risk increased by a
factor of 1.5.20
In patients accepting allogeneic transfusion, preoperative
anaemia is a significant predictor for the likelihood of peri-
operative blood transfusion.14 21 Blood transfusion itself is
associated with postoperative morbidity and mortality, so
that independent analysis of the effects of preoperative
anaemia, perioperative blood transfusions, and postoperative
anaemia outcomes becomes complex. Nevertheless, in a
large retrospective analysis of 300 000 elderly patients
undergoing non-cardiac surgery, a preoperative haematocrit
of ≤39% was associated with a statistically significant
increase in 30-day postoperative mortality.13 This finding
was confirmed by a subsequent retrospective study of 8000
patients undergoing non-cardiac surgery, in which 40% of
the patients had preoperative anaemia, which was associ-
ated with a five-fold increase in 90-day postoperative
mortality.12
The clinical significance of postoperative anaemia
Inflammatory cytokines after surgery and trauma invoke a
response characterized by, among other effects, decreased
iron uptake from the gastrointestinal tract and iron seques-
tration in macrophages, along with a diminished erythroid
response to erythropoietin and decreased erythropoietin pro-
duction.9 Other contributory causes to postoperative
anaemia include pre-existing preoperative anaemia and
traumatic and surgical blood loss. Added to these is an
element of haemodilution occurring as a result of fluid repla-
cement before, during, and after surgery. Normovolaemic
haemodilution is well tolerated due to compensatory mech-
anisms that maintain an adequate myocardial and periph-
eral tissue oxygenation. On the other hand, hypovolaemic
anaemia must be avoided, as the cardiovascular compensa-
tory mechanisms required to maintain oxygen transport in
the setting of anaemia are severely compromised.
Studies in healthy volunteers have shown that Hb concen-
trations as low as 5 g dl21 in patients with normovolaemia do
not result in adverse systemic effects.22 In patients without
CVD who had a preoperative Hb concentration of 6–9 g
dl21 and with little further blood loss, the adjusted odds
ratio (OR) [95% confidence interval (CI)] for mortality was
1.4 (0.5–4.2) compared with those with a preoperative Hb
concentration of .12 g dl21.10 However, in patients with
CVD and the same degree of anaemia, the corresponding
OR was 12.3 (2.5–62.1). This difference persisted through
the various strata of preoperative Hb concentrations up to
11 g dl21. The difference in mortality between patients
with and without CVD was even greater for patients with a
higher blood loss. Patients with more severe illness had a
greater incidence of adverse clinical outcomes (death, infec-
tion, etc.) than less ill patients, independent of any potential
adverse effect related to blood transfusion.23
There is evidence that postoperative anaemia is associated
with adverse cardiovascular events. Episodes of perioperative
myocardial ischaemia on ECG monitoring in patients under-
going radical prostatectomy were related to both the heart
rate and haematocrit levels ,28%.24 A study of high-risk vas-
cular patients undergoing arterial bypass procedures found
similar results: a haematocrit ,28% was significantly associ-
ated with myocardial ischaemia and other cardiac events.25
The impact of a conservative (transfusion trigger, Hb 8 g
dl21) or liberal (Hb 10 g dl21) transfusion strategy on silent
myocardial ischaemic episodes in knee and hip arthroplasties
found no significant difference between the two groups con-
cerning the overall ischaemic load.26 However, in patients
who did experience postoperative ischaemic episodes, they
were significantly prolonged in the liberal group. Neither did
they find any temporal relationship between ischaemia and
transfusion levels or lowest Hb concentrations. One drawback
of the study was that the difference between the mean post-
operative Hb concentrations in the two groups was rather
small (9.9 and 11.1 g dl21).26
Higher perioperative Hb concentrations in patients with
hip fracture were reported to be associated with shorter
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length of hospital stay but not with functional independence
motor mobility.17 Overall, postoperative transfusion reduced
the risk of readmission but did not improve mobility or
reduce mortality. In a pilot study of 84 patients with hip frac-
ture,27 patients with Hb concentrations ,10 g dl21 were ran-
domized to receive blood transfusion either to achieve a
symptomatic transfusion trigger (symptomatic anaemia or
Hb ,8 g dl21) or to achieve threshold transfusions (sufficient
to keep Hb .10 g dl21). The 60-day mortality was 11.9% in
the symptomatic group and 4.8% in the threshold group
[relative risk (RR) 2.5; 95% CI, 0.5–12.2], thus favouring a
more aggressive transfusion therapy. Other outcomes were
similar between the two groups. However, a previous retro-
spective cohort study of 8787 hip fracture patients28 found
that perioperative transfusion to patients with Hb concen-
trations 8 g dl21 or higher did not influence 30- or 90-day
mortality after adjustment for CVD and other risk factors
for death. Recently, a randomized trial of 120 patients
found that patients transfused at higher Hb targets (10 g
dl21) had fewer cardiovascular events and lower mortality
than those at lower Hb targets.29 A multicentre trial compar-
ing ‘aggressive’ and ‘conservative’ blood transfusion therapy
is in progress to address these conflicting data.23
The largest randomized trial to evaluate transfusion trig-
gers to date is in 838 intensive care patients, including
those undergoing surgery.30 Patients were randomized
either to a restrictive transfusion strategy in which patients
received transfusions to keep Hb between 7 and 9 g dl21 or
a liberal strategy with Hb levels maintained between 10
and 12 g dl21. The 30-day mortality in the two groups was
not different, 18.7% and 23.3%, respectively (P¼0.11). The
rate of myocardial infarction was significantly lower in the
restrictive group, 0.7% vs 2.9% (P¼0.02), as was pulmonary
oedema, 5.3% vs 10.7% (P¼0.02).
From these studies, it would appear that for patients
without CVD, the tolerance for postoperative anaemia is
high. In patients with CVD, the tolerance to anaemia is
lower and these patients benefit particularly from anaemia
management. Otherwise, a restrictive transfusion policy
seems equivalent to a liberal policy in terms of mortality,
morbidity, and postoperative mobilization. The most effective
strategy to avoid postoperative anaemia and transfusion
therapy is to identify and correct preoperative anaemia
whenever possible.
Because preoperative anaemia in patients undergoing
elective orthopaedic surgery is associated with increased
likelihood of blood transfusion and increased perioperative
morbidity and mortality, a standardized approach for the
detection, evaluation, and management of anaemia in
this setting has been identified as an unmet medical
need.31 – 33 Reviews have suggested laboratory evaluations
of anaemia based on traditional approaches such as red
cell size (mean corpuscular volume) and serum ferritin
levels.34 35 However, recent advances in the molecular
biology of iron transport in clinical settings of chronic
disease/inflammation now allow more targeted
approaches to anaemia evaluation centred on iron-
restricted erythropoiesis and proactive management with
iron therapy.36
Methods
A multidisciplinary panel of physicians with expertise in
orthopaedic surgery, orthopaedic anaesthesia, haematology,
and epidemiology was convened by the Network for
Advancement of Transfusion Alternatives (NATA) with the
aim of developing practice guidelines for the detection,
evaluation, and management of preoperative anaemia in
elective orthopaedic surgery.
A broad, systematic search strategy applied to Medline
(1966–January 2010) and the Cochrane Register of Con-
trolled Trials (January 2010 edition) was developed to ident-
ify randomized controlled trials and observational studies
evaluating the detection, evaluation, and treatment of
anaemia in orthopaedic surgery. The Medline database was
searched using the MeSH keywords ‘anaemia’, ‘orthopaedics’,
and ‘blood transfusion’. Additional relevant studies not ident-
ified from the electronic search were sought by hand search-
ing of bibliographies of relevant identified articles, and via
consultation of clinical experts in the field. All citation screen-
ing and data extraction was performed independently by two
reviewers.
After completion of the systematic review and
meta-analyses and compilation of the evidence into strategi-
cally structured tables by the two primary reviewers, a task
force consisting of clinical and methodological experts
reviewed findings to assess the evidence and provide appro-
priate recommendations for clinical practice. These findings
were reviewed in the context of two panel meetings, and
via both telephone and electronic communication.
Members of the task force assessed the quantity, quality,
and consistency of the published evidence according to the
method proposed by the Grades of Recommendation Assess-
ment, Development and Evaluation (GRADE) Working
Group,37 using the modified grading system adopted by the
American College of Chest Physicians (Fig. 1).38 The strength
of any recommendation depends on two factors: (i) the
trade-off between benefits, risks, burden, and cost; and (ii)
the confidence in estimates of those benefits and risks
(level of evidence). If the trade-off between benefits and
risks is clear, the recommendation is strong (Grade 1, ‘we rec-
ommend’); if the trade-off is less clear—the best action may
differ depending on circumstances or patient or society
values—the recommendation is weak (Grade 2, ‘we
suggest’). The evidence supporting the recommendation is
graded in three levels according to its methodological
strength: high-quality evidence (A), usually from
meta-analyses or randomized controlled trials; moderate-
quality evidence (B), typically from randomized controlled
trials with significant limitations or observational studies
with large effects; and low-quality evidence (C), usually
from observational studies.37 38 The key studies supporting
the proposed recommendations are listed and annotated in
Supplementary Appendix 1. This framework provides
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reviewers with guidelines to pursue a systematic evaluation
of published evidence with the ultimate goal of providing
physicians with an informed expert opinion of the state of
the evidence for an intervention of interest.
Recommendations
Detection of anaemia
Recommendation 1: We recommend that elective surgical
patients have an Hb level determination as close to
28 days before the scheduled surgical procedure as possible
(Grade 1C).
The Circular of Information for Blood and Blood Products33
has recommended that iron, vitamin B12, folic acid, and ery-
thropoietin be used instead of blood transfusion, ‘if the clini-
cal condition of the patient permits sufficient time for those
agents to promote erythropoiesis . . .’ The key phrase relevant
to this recommendation is, ‘sufficient time . . . to promote ery-
thropoiesis.’ Detection of anaemia as close to 28 days before
surgery is recommended for sufficient time for evaluation
and management.
Recommendation 2: We suggest that the patient’s target
Hb before elective surgery be within the normal range
(female ≥12 g dl21, male ≥13 g dl21), according to the
WHO criteria (Grade 2C).
This recommendation is a suggestion, indicating a lack of
panel consensus and evidence on whether elective surgical
procedures should be cancelled, representing best practices,
for patients who are identified to be anaemic. Delay of elec-
tive scheduled surgery for definitive evaluation of newly
detected anaemia and associated clinical conditions (nutri-
tional deficiency, chronic renal disease, etc.) will benefit
patients and reduce harm, including likelihood of exposure
to blood transfusions.
Evaluation of anaemia
Recommendation 3: We recommend that laboratory testing
be performed to further evaluate anaemia for nutritional
deficiencies, chronic renal insufficiency, and/or chronic
inflammatory disease (Grade 1C).
Unexplained anaemia should be considered as secondary
to some other process,2 9 and the cause of the anaemia must
be evaluated. Laboratory testing must be performed to
further evaluate anaemia for nutritional deficiencies,
chronic renal insufficiency, and/or chronic inflammatory
disease and the cause of the anaemia must be evaluated.
If a screening blood count detects anaemia, evaluation
should begin with an assessment of iron status. The assess-
ment of iron-restricted erythropoiesis needs to distinguish
between absolute iron deficiency, iron sequestration due to
inflammation, and/or functional iron deficiency due to
erythropoietin stimulation.39 The accurate differentiation
of these is difficult using traditional biochemical markers of
iron status, such as serum iron, percentage saturation of
transferrin, and serum ferritin.9 As ferritin is an acute-phase
reactant, traditional laboratory thresholds of ,12 mg litre21
may be suitable for identifying absolute iron deficiency in
normal individuals, but not in patients with any evidence of
an inflammatory process.36 Correlation of iron stores with
ferritin values has demonstrated that ferritin levels must
exceed 30 mg litre21 to achieve a 92% sensitivity for exclu-
sion of absolute iron deficiency.40 For patients without
chronic renal disease, ferritin levels .100 mg litre21
confirm the presence of stored iron.9 36
When absolute iron deficiency is detected, referral to a
gastroenterologist to rule out a gastrointestinal malignancy
as a source of chronic blood loss is indicated.38 If laboratory
evaluation or a diagnostic trial of iron therapy rules out
absolute iron deficiency, measurement of serum creatinine
Grading system
Strength of recommendation: is risk/benefit clear?
Yes  strong recommendation=Grade 1: ‘we recommend’
No  weak recommendation=Grade 2: ‘we suggest’
High-quality evidence=A (meta-analyses, randomized controlled trials)
Moderate-quality evidence=B (randomized controlled trials with limitations,
observational studies with large effects)
Low- or very low-quality evidence=C (obervational studies, randomized
controlled tried with major limitations)
Grade 1A
Grade 1B
Grade 1C
Grade 2A
Grade 2B
Grade 2C
Grade of recommendation=6 possible grades
Quality of evidence
Fig 1 The grading system used for assessment.
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and glomerular filtration rate (GFR) may indicate CKD and the
need for referral to a nephrologist. If ferritin, iron saturation
values, or both or other markers of iron-restricted erythropoi-
esis are inconclusive, further evaluation to rule out iron
deficiency or iron sequestration due to inflammation/
chronic disease is necessary. A therapeutic trial of oral iron
therapy would confirm absolute iron deficiency. No response
to iron therapy may not rule out absolute iron deficiency
because of patient non-compliance,39 ongoing blood (iron)
losses in excess of oral iron absorption,40 and/or diminished
gastrointestinal absorption of iron due to inflammation.9
Additionally, iron-restricted erythropoiesis due to iron
sequestration, functional deficiency, or both must be con-
sidered. In these instances, management strategies that
include i.v. iron, with or without erythropoiesis-stimulating
agents (ESA) therapy, should be considered.41
Management of anaemia
Treatment of nutritional deficiencies
Recommendation 4: We recommend that nutritional
deficiencies be treated (Grade 1C).
Nutritional deficiencies must be treated. Iron supplemen-
tation is indicated in the presence of confirmed iron
deficiency anaemia. The effectiveness of oral iron in the
management of preoperative anaemia has been demon-
strated in patients undergoing orthopaedic41 42 and colorec-
tal cancer43 44 surgery. In the absence of preoperative iron
supplementation, postoperative iron supplementation has
not been shown to be effective.45 – 49
Three small series of orthopaedic surgery patients, under-
going repair of hip fracture50 51 or joint replacement and back
surgery,52 demonstrated the feasibility of parenteral iron
supplementation in the preoperative management of iron-
deficiency anaemia, particularly if there was a short interval
before surgery. An expert panel recently reviewed the role of
i.v. iron in the management of perioperative anaemia and
concluded that patients with preoperative anaemia due to
iron deficiency or chronic disease should receive preoperative
treatment with oral or i.v. iron, depending on the timescale
before surgery, tolerance of oral iron, and iron status.53
Stimulation of erythropoiesis
Recommendation 5: We suggest that ESA be used for
anaemic patients in whom nutritional deficiencies have
been ruled out, corrected, or both (Grade 2A).
The use of ESA therapy in patients undergoing major, elec-
tive surgery is well established on the basis of controlled, ran-
domized trials and is approved for use in this setting.
However, recent concerns regarding the RR/benefit of these
agents and their appropriate use in patients with chronic
renal disease,54 – 61 in patients with anaemia related to
cancer or chemotherapy,62 – 70 and in patients undergoing
elective surgery71 have resulted in a Grade 2 or ‘suggested’
recommendation.
The use of ESAs in patients with anaemia undergoing
elective orthopaedic (hip, knee, and spine) surgery was
reviewed under the auspices of NATA.72 A meta-analysis of
41 published studies [eight studies of ESA alone,71 73 – 79 22
studies of ESA augmented with preoperative autologous
blood donation (PABD),39 80 – 100 seven studies of ESA com-
pared with PABD,71 84 101 – 105 and four studies of ESA and
other comparators]106 – 109 was performed. Pooled estimates
of transfusion exposure demonstrated clinically important
benefit for both rHuEPO alone (RR, 0.44; 95% CI, 0.31–0.64)
and rHuEPO augmented by PABD (RR, 0.61; 95% CI, 0.49–
0.75). Although sufficient data were available for patients
undergoing hip surgery, a large number of studies performed
in patients undergoing a mixture of surgical procedures, and
a failure to report indication-specific associations with the
intervention, limit the ability to make judgement on the
effectiveness of rHuEPO in patients undergoing non-hip pro-
cedures such as knee and spinal surgery. Taking account of
all the studies, the risk of deep vein thrombosis was
increased with the use of rHuEPO [Peto OR of 1.66 (95% CI
1.10–2.48)] but was inconclusive on the risk of mortality,
myocardial infarction, and cerebrovascular accidents due to
their low incidence.
Anaemia of chronic disease is a diagnosis of exclusion.7
However, the following are considered evidence of anaemia
of chronic disease: anaemia with no evidence of nutritional
deficiencies or chronic renal disease, and the presence of
an associated chronic disease. In the presence of a low Hb
and normal mean corpuscular volume, a reticulocyte count
and serum creatinine level should be measured and GFR cal-
culated. A nephrology consultation is appropriate if an abnor-
mal creatinine level or GFR is present to evaluate for possible
haemolysis, blood loss, or chronic renal disease.
Patients should receive iron supplementation throughout
the course of ESA therapy, to optimize the dose–response
relationship for ESA therapy and red blood cell production
in the pre-surgical setting.110 ESA therapy with iron sup-
plementation is effective in reducing subsequent need for
allogeneic transfusion.72
Detection, evaluation, and management of
preoperative of anaemia: an algorithm
We propose an algorithm for the detection, evaluation, and
management of preoperative anaemia based on the above
recommendations (Fig. 2).
If anaemia is detected on a screening sample, evaluation
is necessary and begins with an assessment of iron status. If
serum ferritin, transferrin saturation levels, or both indicate
absolute iron deficiency, referral to a gastroenterologist to
rule out a gastrointestinal malignancy as a source of
chronic blood loss may be indicated.
If serum ferritin, transferrin saturation values, or both rule
out absolute iron deficiency, serum creatinine and GFR deter-
mination may indicate CKD and the need for referral to a
nephrologist.
When serum ferritin, transferrin saturation values, or both
are inconclusive, further evaluation to rule out absolute iron
deficiency or inflammation/chronic disease is necessary. A
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therapeutic trial of iron would confirm absolute iron deficiency.
No response to iron therapy would indicate the anaemia of
chronic disease, suggesting that ESA therapy be initiated.
These recommendations are intended to provide guidance
for preoperative evaluation in the elective surgical patient.
Limiting preadmission testing to a few days before the
scheduled operative procedure precludes the opportunity to
evaluate and manage the patient with unexplained
anaemia. The recommended time frame of testing 4 weeks
before the scheduled elective procedure ensures that
anaemia can be detected, evaluated, and managed appro-
priately before elective surgery.
Anaemia should be viewed as a serious and treatable
medical condition, rather than as simply an abnormal labora-
tory value. Anaemia is a common condition in surgical
patients and is independently associated with increased
mortality. The diagnosis of an unexpected anaemia in
patients undergoing elective surgery in which significant
blood loss is anticipated should be considered an indication
for rescheduling surgery until the evaluation is completed.
The presence of preoperative anaemia is significantly associ-
ated with morbidity and mortality after surgery, thus war-
ranting this recommendation. Treatment of postoperative
anaemia should be the focus of investigations for the
reduction of perioperative risk. We conclude that implemen-
tation of anaemia management in the elective surgery
setting will improve patient outcome.
Supplementary material
Supplementary material is available at British Journal of
Anaesthesia online.
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deficiency
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therapy
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Fig 2 Proposed algorithm for the detection, evaluation, and management of preoperative anaemia. SF, serum ferritin; TSAT, transferrin saturation.
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